BioTime Aktie

1,43 EUR +0,03 EUR +2,14 %

24.10.2025

BMN

1,70 USD ±0,00 USD ±0,00 %

nachbörslich24.10.2025

BTT

BioTime jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.320,24 Mio. EUR

Div. Rendite0,00%

WKNA2PP89

ISINUS53566P1093

SymbolLCTX

BioTime Aktien News

Sortieren:Datum Meistgelesen

06.01.25BusinesswireLineage Cell Therapeutics Issues Letter to Stockholders

21.11.24BusinesswireLineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

20.11.24BusinesswireLineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

WerbungBioTime-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

14.11.24BusinesswireLineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07.11.24BusinesswireLineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

14.10.24BusinesswireLineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

25.09.24BusinesswireOpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

18.09.24BusinesswireLineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

13.08.24BusinesswireLineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08.08.24BusinesswireLineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

01.08.24BusinesswireLineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

02.07.24BusinesswireLineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

30.05.24BusinesswireLineage to Present at 2024 BIO International Convention

21.05.24BusinesswireLineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

09.05.24BusinesswireLineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

06.05.24BusinesswireOpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

02.05.24BusinesswireLineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

30.04.24BusinesswireLineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

29.04.24BusinesswireLineage Announces Changes to Board of Directors

01.04.24BusinesswireLineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

18.03.24BusinesswireLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

13.03.24BusinesswireRG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

11.03.24BusinesswireRG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

07.03.24BusinesswireLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

29.02.24BusinesswireLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

13.02.24BusinesswireLineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

09.02.24BusinesswireLineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

06.02.24BusinesswireLineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

16.01.24BusinesswireRG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

18.12.23BusinesswireLineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

09.11.23BusinesswireLineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

01.11.23BusinesswireLineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023

24.10.23BusinesswireRG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

11.10.23BusinesswireLineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

05.10.23BusinesswireRG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

19.09.23BusinesswireLineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023

13.09.23BusinesswireRG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress

11.09.23BusinesswireLineage to Present at 2023 International Spinal Research Trust Network Meeting

06.09.23BusinesswireLineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics

29.08.23BusinesswireLineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference

BioTime News

BioTime News: auf dieser Seite finden Sie alle BioTime News und Nachrichten zur BioTime Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch BioTime News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um BioTime News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.